FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Sela

Research Profile

Living Beings

Chemicals & Drugs

Disorders

Anatomy

Genes & Molecular Sequences

Amino Acid Sequences

Concepts & Ideas

Molecular Sequence Data

Co-author Network

Publications

TOP 3
Georg Mahlknecht; Maicol Mancini; Ruth Maron; Bilha Schechter; Michael Sela; Yosef Yarden
Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth.
Rina Aharoni; Yaniv Assaf; Tamar Blumenfeld-Katzir; Raya Eilam; Efrat Sasson; Michael Sela; Ruth Arnon
Magnetic resonance imaging characterization of different experimental autoimmune encephalomyelitis models and the therapeutic effect of glatiramer acetate.
Daniela A Ferraro; Nadège Gaborit; Sara Lavi; Moshit Lindzen; Ruth Maron; Fresia Pareja; Ziv Porat; Michael Sela; Nir Ben-Chetrit; Hadas Cohen-Dvashi; Yosef Yarden
Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Sela (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Georg Mahlknecht; Maicol Mancini; Ruth Maron; Bilha Schechter; Michael Sela; Yosef Yarden
Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth.
Proceedings of the National Academy of Sciences of the United States of America 2013;110(20):8170-5.
2013: Rina Aharoni; Yaniv Assaf; Tamar Blumenfeld-Katzir; Raya Eilam; Efrat Sasson; Michael Sela; Ruth Arnon
Magnetic resonance imaging characterization of different experimental autoimmune encephalomyelitis models and the therapeutic effect of glatiramer acetate.
Experimental neurology 2013;240():130-44.
2013: Daniela A Ferraro; Nadège Gaborit; Sara Lavi; Moshit Lindzen; Ruth Maron; Fresia Pareja; Ziv Porat; Michael Sela; Nir Ben-Chetrit; Hadas Cohen-Dvashi; Yosef Yarden
Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR.
Proceedings of the National Academy of Sciences of the United States of America 2013;110(5):1815-20.
2012: Rina Aharoni; Raya Eilam; Liat Hayardeny; Ravit Saada; Michael Sela; Ruth Arnon
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.
Journal of neuroimmunology 2012;251(1-2):14-24.
2011: Anna Emde; Georg Mahlknecht; Kerstin Maslak; Kurt Possinger; Benjamin Ribba; Michael Sela; Yosef Yarden
Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance.
Translational oncology 2011;4(5):293-300.
2011: A Emde; C-R Pradeep; D A Ferraro; N Ben-Chetrit; Michael Sela; B Ribba; Zvi Kam; Yosef Yarden
Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth.
Oncogene 2011;30(14):1631-42.
2009: Gabriel Nussbaum; Shimon Ben-Adi; Tamar Genzler; Michael Sela; Graciela Rosen
Involvement of Toll-like receptors 2 and 4 in the innate immune response to Treponema denticola and its outer sheath components.
Infection and immunity 2009;77(9):3939-47.
2009: Tsipi Ben-Kasus; Bilha Schechter; Sara Lavi; Yosef Yarden; Michael Sela
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(9):3294-9.
2008: Rina Aharoni; Avia Herschkovitz; Raya Eilam; Michal Blumberg-Hazan; Michael Sela; Wolfgang Bruck; Ruth Arnon
Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(32):11358-63.
2007: Hava Ben David; Amir Sharabi; Molly Dayan; Michael Sela; Edna Mozes
The role of CD8+CD28 regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligand.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(44):17459-64.
2007: Tsipi Ben-Kasus; Bilha Schechter; Michael Sela; Yosef Yarden
Cancer therapeutic antibodies come of age: targeting minimal residual disease.
Molecular oncology 2007;1(1):42-54.
2007: Hava Ben David; B Venkata Aruna; Michael Sela; Edna Mozes
A dual altered peptide ligand inhibits myasthenia gravis associated responses by inducing phosphorylated extracellular-regulated kinase 1,2 that upregulates CD4+CD25+Foxp3+ cells.
Scandinavian journal of immunology 2007;65(6):567-76.
2006: Hava Ben David; Badiga Venkata Aruna; Rony Seger; Michael Sela; Edna Mozes
A 50-kDa ERK-like protein is up-regulated by a dual altered peptide ligand that suppresses myasthenia gravis-associated responses.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(48):18232-7.
2006: Badiga Venkata Aruna; Michael Sela; Edna Mozes
Down-regulation of T cell responses to AChR and reversal of EAMG manifestations in mice by a dual altered peptide ligand via induction of CD4+ CD25+ regulatory cells.
Journal of neuroimmunology 2006;177(1-2):63-75.
2006: Badiga Venkata Aruna; Hava Ben David; Michael Sela; Edna Mozes
A dual altered peptide ligand down-regulates myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up-regulation of Fas-FasL-mediated apoptosis.
Immunology 2006;118(3):413-24.
2006: Michael Sela
Immunomodulatory vaccines against autoimmune diseases.
Rejuvenation research 2006;9(1):126-33.
2005: Rina Aharoni; Raya Eilam; Hagit Domev; Galya Labunskay; Michael Sela; Ruth Arnon
The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(52):19045-50.
2005: Badiga Venkata Aruna; Michael Sela; Edna Mozes
Suppression of myasthenogenic responses of a T cell line by a dual altered peptide ligand by induction of CD4+CD25+ regulatory cells.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(29):10285-90.
2005: Lilach Friedman; Ariel Rinon; Bilha Schechter; Ljuba Lyass; Sara Lavi; Sarah S Bacus; Michael Sela; Yosef Yarden
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(6):1915-20.
2005: Hava Ben David; Michael Sela; Edna Mozes
Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4+CD25+-regulated events leading to apoptosis.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(6):2028-33.
2005: Rina Aharoni; Alexander Yussim; Michael Sela; Ruth Arnon
Combined treatment of glatiramer acetate and low doses of immunosuppressive drugs is effective in the prevention of graft rejection.
International immunopharmacology 2005;5(1):23-32.
2004: Dvora Teitelbaum; Rina Aharoni; Ety Klinger; Rivka Kreitman; Emanuel Raymond; Arthur Malley; Rona Shofti; Michael Sela; Ruth Arnon
Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies.
Annals of the New York Academy of Sciences 2004;1029():239-49.
2004: Michael Sela; Maurice R Hilleman
Therapeutic vaccines: realities of today and hopes for tomorrow.
Proceedings of the National Academy of Sciences of the United States of America 2004;101 Suppl 2():14559.
2004: Michael Sela; Edna Mozes
Therapeutic vaccines in autoimmunity.
Proceedings of the National Academy of Sciences of the United States of America 2004;101 Suppl 2():14586-92.
2004: Molly Dayan; Zev M Sthoeger; Alex Neiman; Jacob Abarbanel; Michael Sela; Edna Mozes
Immunomodulation by a dual altered peptide ligand of autoreactive responses to the acetylcholine receptor of peripheral blood lymphocytes of patients with myasthenia gravis.
Human immunology 2004;65(6):571-7.
2003: Michael Sela
From proteins and protein models to their use in immunology and immunotherapy.
The Journal of biological chemistry 2003;278(49):48507-19.
2003: Dvora Teitelbaum; Talma Brenner; Oded Abramsky; Rina Aharoni; Michael Sela; Ruth Arnon
Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy.
Multiple sclerosis (Houndmills, Basingstoke, England) 2003;9(6):592-9.
2003: Rina Aharoni; BASAK KAYHAN; Raya Eilam; Michael Sela; Ruth Arnon
Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(24):14157-62.
2003: Ruth Arnon; Michael Sela
Immunomodulation by the copolymer glatiramer acetate.
Journal of molecular recognition : JMR 2003;16(6):412-21.
2003: Miri Paas-Rozner; Michael Sela; Edna Mozes
A dual altered peptide ligand down-regulates myasthenogenic T cell responses by up-regulating CD25- and CTLA-4-expressing CD4+ T cells.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(11):6676-81.
2002: Michael Sela; Ruth Arnon; Bilha Schechter
Therapeutic vaccines: realities of today and hopes for the future.
Drug discovery today 2002;7(12):664-73.
2002: Rina Aharoni; Asher Meshorer; Michael Sela; Ruth Arnon
Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system.
Journal of neuroimmunology 2002;126(1-2):58-68.
2001: Miri Paas-Rozner; Michael Sela; Edna Mozes
The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(22):12642-7.
2001: Rina Aharoni; Dvora Teitelbaum; Ruth Arnon; Michael Sela
Copolymer 1 inhibits manifestations of graft rejection.
Transplantation 2001;72(4):598-605.
2001: Michael Sela; Dvora Teitelbaum
Glatiramer acetate in the treatment of multiple sclerosis.
Expert opinion on pharmacotherapy 2001;2(7):1149-65.
2001: Talma Brenner; Ruth Arnon; Michael Sela; Oded Abramsky; Zeev Meiner; R Riven-Kreitman; N Tarcik; Dvora Teitelbaum
Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone.
Journal of neuroimmunology 2001;115(1-2):152-60.
2001: Anat Faber-Elmann; Valentin Grabovsky; Molly Dayan; Michael Sela; Ronen Alon; Edna Mozes
An altered peptide ligand inhibits the activities of matrix metalloproteinase-9 and phospholipase C, and inhibits T cell interactions with VCAM-1 induced in vivo by a myasthenogenic T cell epitope.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2001;15(1):187-194.
2000: Nora Vaisman; A Nissim; LN Klapper; Boaz Tirosh; Yosef Yarden; Michael Sela
Specific inhibition of the reaction between a tumor-inhibitory antibody and the ErbB-2 receptor by a mimotope derived from a phage display library.
Immunology letters 2000;75(1):61-7.
2000: Anat Faber-Elmann; Valentin Grabovsky; Molly Dayan; Michael Sela; Ronen Alon; Edna Mozes
Cytokine profile and T cell adhesiveness to endothelial selectins: in vivo induction by a myasthenogenic T cell epitope and immunomodulation by a dual altered peptide ligand.
International immunology 2000;12(12):1651-8.
2000: Gil Levkowitz; Shlomo Oved; LN Klapper; Daniel Harari; Sara Lavi; Michael Sela; Yosef Yarden
c-Cbl is a suppressor of the neu oncogene.
The Journal of biological chemistry 2000;275(45):35532-9.
2000: Rina Aharoni; Dvora Teitelbaum; O Leitner; Asher Meshorer; Michael Sela; Ruth Arnon
Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(21):11472-7.
2000: E Hurwitz; LN Klapper; M Wilchek; Yosef Yarden; Michael Sela
Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies.
Cancer immunology, immunotherapy : CII 2000;49(4-5):226-34.
2000: LN Klapper; Hadassa Waterman; Michael Sela; Yosef Yarden
Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2.
Cancer research 2000;60(13):3384-8.
2000: Jonathan Kipnis; Eti Yoles; Ziv Porat; A Cohen; Felix Mor; Michael Sela; Irun R Cohen; Michal Schwartz
T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(13):7446-51.
2000: Miri Paas-Rozner; Molly Dayan; Y Paas; Jean-Pierre Changeux; I Wirguin; Michael Sela; Edna Mozes
Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(5):2168-73.
2000: Michael Sela
Structural components responsible for peptide antigenicity.
Applied biochemistry and biotechnology 2000;83(1-3):63-70; discussion 145-53.
2000: LN Klapper; M H Kirschbaum; Michael Sela; Yosef Yarden
Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors.
Advances in cancer research 2000;77():25-79.
1999: Michael Sela
Specific vaccines against autoimmune diseases.
Comptes rendus de l'Académie des sciences. Série III, Sciences de la vie 1999;322(11):933-8.
1999: Masha Fridkis-Hareli; Rina Aharoni; Dvora Teitelbaum; Ruth Arnon; Michael Sela; Jack L Strominger
Binding of random copolymers of three amino acids to class II MHC molecules.
International immunology 1999;11(5):635-41.
1999: LN Klapper; S Glathe; Nora Vaisman; N E Hynes; glenn andrews; Michael Sela; Yosef Yarden
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(9):4995-5000.
1999: Masha Fridkis-Hareli; John Neveu; R A Robinson; William Stratton Lane; L Gauthier; Kai W Wucherpfennig; Michael Sela; Jack L Strominger
Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(8):4697-704.
1999: Dvora Teitelbaum; Ruth Arnon; Michael Sela
Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(7):3842-7.
1999: Rina Aharoni; Dvora Teitelbaum; Ruth Arnon; Michael Sela
Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(2):634-9.
1999: Michael Sela
The concept of specific immune treatment against autoimmune diseases.
International reviews of immunology 1999;18(3):201-16.
1998: Anat Faber-Elmann; Miri Paas-Rozner; Michael Sela; Edna Mozes
Altered peptide ligands act as partial agonists by inhibiting phospholipase C activity induced by myasthenogenic T cell epitopes.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(24):14320-5.
1998: Rina Aharoni; Dvora Teitelbaum; Michael Sela; Ruth Arnon
Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1.
Journal of neuroimmunology 1998;91(1-2):135-46.
1998: Michael Sela
Probing into the realm of proteins and immunity.
Protein science : a publication of the Protein Society 1998;7(7):1653-9.
1998: Lenferink Anne; Ronit Pinkas-Kramarski; Monique L M van De Poll; MJ van Vugt; LN Klapper; E Tzahar; Hadassa Waterman; Michael Sela; Everardus J J van Zoelen; Yosef Yarden
Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers.
The EMBO journal 1998;17(12):3385-97.
1998: Y Katz-Levy; Molly Dayan; I Wirguin; Mati Fridkin; Michael Sela; Edna Mozes
Single amino acid analogs of a myasthenogenic peptide modulate specific T cell responses and prevent the induction of experimental autoimmune myasthenia gravis.
Journal of neuroimmunology 1998;85(1):78-86.
1998: Ronit Pinkas-Kramarski; Lenferink Anne; Sarah S Bacus; Ljuba Lyass; Monique L M van De Poll; LN Klapper; E Tzahar; Michael Sela; Everardus J J van Zoelen; Yosef Yarden
The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
Oncogene 1998;16(10):1249-58.
1997: Rina Aharoni; Dvora Teitelbaum; Michael Sela; Ruth Arnon
Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(20):10821-6.
1997: E Tzahar; Ronit Pinkas-Kramarski; JD Moyer; LN Klapper; Iris Alroy; Gil Levkowitz; Maya Shelly; S Henis; Miriam Eisenstein; BJ Ratzkin; Michael Sela; glenn andrews; Yosef Yarden
Bivalence of EGF-like ligands drives the ErbB signaling network.
The EMBO journal 1997;16(16):4938-50.
1997: Rina Aharoni; PG Schlegel; Dvora Teitelbaum; O Roikhel-Karpov; Y Chen; Ruth Arnon; Michael Sela; Nelson J Chao
Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease.
Immunology letters 1997;58(2):79-87.
1997: Masha Fridkis-Hareli; Dvora Teitelbaum; Israel Pecht; Ruth Arnon; Michael Sela
Binding of copolymer 1 and myelin basic protein leads to clustering of class II MHC molecules on antigen-presenting cells.
International immunology 1997;9(7):925-34.
1997: Avi Karni; Einat Zisman; Y Katz-Levy; Miri Paas-Rozner; Molly Dayan; Chaim Brautbar; Oded Abramsky; Michael Sela; Edna Mozes
Reactivity of T cells from seronegative patients with myasthenia gravis to T cell epitopes of the human acetylcholine receptor.
Neurology 1997;48(6):1638-42.
1997: Michael Sela; Einat Zisman
Different roles of D-amino acids in immune phenomena.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1997;11(6):449-56.
1997: LN Klapper; Nora Vaisman; E Hurwitz; Ronit Pinkas-Kramarski; Yosef Yarden; Michael Sela
A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors.
Oncogene 1997;14(17):2099-109.
1997: Dvora Teitelbaum; Michael Sela; Ruth Arnon
Copolymer 1 from the laboratory to FDA.
Israel journal of medical sciences 1997;33(4):280-4.
1997: Y Katz-Levy; Miri Paas-Rozner; SL Kirshner; Molly Dayan; Einat Zisman; Mati Fridkin; I Wirguin; Michael Sela; Edna Mozes
A peptide composed of tandem analogs of two myasthenogenic T cell epitopes interferes with specific autoimmune responses.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(7):3200-5.
1997: Dvora Teitelbaum; Ruth Arnon; Michael Sela
Cop 1 as a candidate drug for multiple sclerosis.
Journal of neural transmission. Supplementum 1997;49():85-91.
1997: Dvora Teitelbaum; Ruth Arnon; Michael Sela
Copolymer 1: from basic research to clinical application.
Cellular and molecular life sciences : CMLS 1997;53(1):24-8.
1996: S L Kirshner; Einat Zisman; Mati Fridkin; Michael Sela; Edna Mozes
Altered peptide ligands of a myasthenogenic epitope as modulators of specific T-cell responses.
Scandinavian journal of immunology 1996;44(5):512-21.
1996: Ronit Pinkas-Kramarski; L Soussan; Hadassa Waterman; Gil Levkowitz; Iris Alroy; LN Klapper; S Lavi; Rony Seger; B J Ratzkin; Michael Sela; Yosef Yarden
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.
The EMBO journal 1996;15(10):2452-67.
1996: PG Schlegel; Rina Aharoni; Y Chen; J Chen; Dvora Teitelbaum; Ruth Arnon; Michael Sela; Nelson J Chao
A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(10):5061-6.
1996: Einat Zisman; Y Katz-Levy; Molly Dayan; S L Kirshner; Miri Paas-Rozner; Avi Karni; Oded Abramsky; Chaim Brautbar; Mati Fridkin; Michael Sela; Edna Mozes
Peptide analogs to pathogenic epitopes of the human acetylcholine receptor alpha subunit as potential modulators of myasthenia gravis.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(9):4492-7.
1996: Ruth Arnon; Michael Sela; Dvora Teitelbaum
New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis.
Journal of neurology 1996;243(4 Suppl 1):S8-13.
1996: Avraham Ben-Nun; Itzhak Mendel; R Bakimer; Masha Fridkis-Hareli; Dvora Teitelbaum; Ruth Arnon; Michael Sela; Nicole Kerlero de Rosbo
The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease.
Journal of neurology 1996;243(4 Suppl 1):S14-22.
1996: Gil Levkowitz; LN Klapper; E Tzahar; A Freywald; Michael Sela; Yosef Yarden
Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins.
Oncogene 1996;12(5):1117-25.
1996: Dvora Teitelbaum; Masha Fridkis-Hareli; Ruth Arnon; Michael Sela
Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses.
Journal of neuroimmunology 1996;64(2):209-17.
1996: Michael Sela; Israel Pecht
The nature of the antigen.
Advances in protein chemistry 1996;49():289-328.
1995: Einat Zisman; Chaim Brautbar; Michael Sela; Oded Abramsky; S Battat; S L Kirshner; Y Katz-Levy; Molly Dayan; Edna Mozes
Binding of peptides of the human acetylcholine receptor alpha-subunit to HLA class II of patients with myasthenia gravis.
Human immunology 1995;44(3):121-30.
1995: R Adler; E Hurwitz; J R Wands; Michael Sela; Daniel Shouval
Specific targeting of adriamycin conjugates with monoclonal antibodies to hepatoma associated antigens to intrahepatic tumors in athymic mice.
Hepatology (Baltimore, Md.) 1995;22(5):1482-7.
1995: Masha Fridkis-Hareli; Dvora Teitelbaum; Ruth Arnon; Michael Sela
Synthetic copolymer 1 and myelin basic protein do not require processing prior to binding to class II major histocompatibility complex molecules on living antigen-presenting cells.
Cellular immunology 1995;163(2):229-36.
1995: E Hurwitz; I Stancovski; Michael Sela; Yosef Yarden
Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(8):3353-7.
1995: Dan S Tawfik; R Chap; Bernard S Green; Michael Sela; Zelig Eshhar
Unexpectedly high occurrence of catalytic antibodies in MRL/lpr and SJL mice immunized with a transition-state analog: is there a linkage to autoimmunity?
Proceedings of the National Academy of Sciences of the United States of America 1995;92(6):2145-9.
1995: Michael Sela; S L Kirshner; Y Katz-Levy; Einat Zisman; Edna Mozes
Dominant epitopes and synthetic peptides in myasthenia gravis.
Israel journal of medical sciences 1995;31(1):10-2.
1994: Einat Zisman; Michael Sela; Avraham Ben-Nun; Edna Mozes
Dichotomy between the T and the B cell epitopes of the synthetic polypeptide (T,G)-A--L.
European journal of immunology 1994;24(10):2497-505.
1994: Masha Fridkis-Hareli; Dvora Teitelbaum; E Gurevich; Israel Pecht; Chaim Brautbar; O J Kwon; T Brenner; Ruth Arnon; Michael Sela
Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(11):4872-6.
1994: I Stancovski; Michael Sela; Yosef Yarden
Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase.
Cancer treatment and research 1994;71():161-91.
1993: I Stancovski; Daniel G Schindler; Tova Waks; Yosef Yarden; Michael Sela; Zelig Eshhar
Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors.
Journal of immunology (Baltimore, Md. : 1950) 1993;151(11):6577-82.
1993: Y Katz-Levy; S L Kirshner; Michael Sela; Edna Mozes
Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(15):7000-4.
1993: K A Muszkat; Bilha Schechter; Michael Sela
Aromatic side-chain interactions as the origin of immunological diversity in the TyrTyrGluGlu and TyrGluTyrGlu epitopes: NMR and fluorescence evidence.
International immunology 1993;5(6):591-7.
1993: Einat Zisman; Molly Dayan; Michael Sela; Edna Mozes
Ia-antigen-T-cell interactions for a thymus-independent antigen composed of D amino acids.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(3):994-8.
1993: Dan S Tawfik; Bernard S Green; R Chap; Michael Sela; Zelig Eshhar
catELISA: a facile general route to catalytic antibodies.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(2):373-7.
1992: K A Muszkat; Bilha Schechter; Michael Sela
Structural origin of the immunological diversity of two closely related tetrapeptides: CIDNP study of TyrTyrGluGlu and TyrGluTyrGlu epitopes.
Molecular immunology 1992;29(9):1049-54.
1992: I Stancovski; Elior Peles; R Ben Levy; R Lemprecht; Zvi Kelman; R Goldman-Michael; E Hurwitz; Sarah S Bacus; Michael Sela; Yosef Yarden
Signal transduction by the neu/erbB-2 receptor: a potential target for anti-tumor therapy.
The Journal of steroid biochemistry and molecular biology 1992;43(1-3):95-103.
1992: Michael Sela; Edna Mozes; Einat Zisman; K A Muszkat; Bilha Schechter
A tale of two peptides, TyrTyrGluGlu and TyrGluTyrGlu, and their diverse immune behaviour.
Behring Institute Mitteilungen 1992;(91):54-66.
1992: E Hurwitz; R Adler; Daniel Shouval; H Takahashi; J R Wands; Michael Sela
Immunotargeting of daunomycin to localized and metastatic human colon adenocarcinoma in athymic mice.
Cancer immunology, immunotherapy : CII 1992;35(3):186-92.
1992: Michael Sela; Ruth Arnon
Synthetic approaches to vaccines for infectious and autoimmune diseases.
Vaccine 1992;10(14):991-9.
1992: Dvora Teitelbaum; Ron Milo; Ruth Arnon; Michael Sela
Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(1):137-41.
1991: Einat Zisman; Michael Sela; Edna Mozes
Direct binding of a synthetic multichain polypeptide to class II major histocompatibility complex molecules on antigen-presenting cells and stimulation of a specific T-cell line require processing of the polypeptide.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(21):9738-42.
1991: Dvora Teitelbaum; Rina Aharoni; Michael Sela; Ruth Arnon
Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(21):9528-32.
1991: I Stancovski; E Hurwitz; O Leitner; A Ullrich; Yosef Yarden; Michael Sela
Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(19):8691-5.
1991: Bilha Schechter; Ruth Arnon; Meir Wilchek; J Schlessinger; E Hurwitz; E Aboud-Pirak; Michael Sela
Indirect immunotargeting of cis-Pt to human epidermoid carcinoma KB using the avidin-biotin system.
International journal of cancer. Journal international du cancer 1991;48(2):167-72.
1990: E Hurwitz; I Stancovski; Meir Wilchek; Daniel Shouval; H Takahashi; J R Wands; Michael Sela
A conjugate of 5-fluorouridine-poly(L-lysine) and an antibody reactive with human colon carcinoma.
Bioconjugate chemistry 1990;1(4):285-90.
1990: Eithan Galun; Daniel Shouval; R Adler; M Shahaar; M Wilchek; E Hurwitz; Michael Sela
The effect of anti-alpha-fetoprotein-adriamycin conjugate on a human hepatoma.
Hepatology (Baltimore, Md.) 1990;11(4):578-84.
1989: Michael Sela
Some reflections on autoimmunity.
Israel journal of medical sciences 1989;25(12):697-8.
1989: Ruth Arnon; Dvora Teitelbaum; Michael Sela
Suppression of experimental allergic encephalomyelitis by COP1--relevance to multiple sclerosis.
Israel journal of medical sciences 1989;25(12):686-9.
1989: Abraham Zlotogorski; Meir Nyska; Michael Sela; A Nyska; Mervyn S Gotsman
Nifedipine-induced gingival hyperplasia: case reports and literature review.
Israel journal of medical sciences 1989;25(8):453-5.
1989: E Aboud-Pirak; E Hurwitz; F Bellot; J Schlessinger; Michael Sela
Inhibition of human tumor growth in nude mice by a conjugate of doxorubicin with monoclonal antibodies to epidermal growth factor receptor.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(10):3778-81.
1988: E Aboud-Pirak; E Hurwitz; M E Pirak; F Bellot; J Schlessinger; Michael Sela
Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice.
Journal of the National Cancer Institute 1988;80(20):1605-11.
1988: Dvora Teitelbaum; Rina Aharoni; Ruth Arnon; Michael Sela
Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(24):9724-8.
1988: Daniel Shouval; R Adler; J R Wands; E Hurwitz; K J Isselbacher; Michael Sela
Doxorubicin conjugates of monoclonal antibodies to hepatoma-associated antigens.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(21):8276-80.